<?xml version="1.0" encoding="UTF-8"?>
<p>According to the guidelines implemented in China for COVID-19 infection, IFNα is to be administered by inhalation (five million U twice a day), combined with the antiviral ribavirin [
 <xref rid="B62-pharmaceuticals-13-00096" ref-type="bibr">62</xref>]. Clinical trials have been recently registered to assess a combination of lopinavir/ritonavir and IFNα2b (ChiCTR2000029387) or a combination of lopinavir/ritonavir with ribavirin and subcutaneously-administered IFNß1b (NCT04276688) for the treatment of COVID-19; see 
 <xref rid="pharmaceuticals-13-00096-t001" ref-type="table">Table 1</xref>. 
</p>
